{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:37:39Z","timestamp":1790221059009,"version":"4.1.0"},"reference-count":24,"publisher":"Portland Press Ltd.","issue":"3","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>The present study sought to identify confounding factors for the interpretation of copeptin levels in healthy individuals. The natriuretic peptides are recognized as diagnostic and prognostic tools in HF (heart failure). Interpretation of BNP (brain natriuretic peptide) and NTproBNP (N-terminal pro-BNP) levels is multifaceted as their secretion is influenced by many variables. A newly identified glycopeptide called copeptin is comparable with the natriuretic peptides in the diagnosis and prognosis of HF and as a prognostic biomarker after AMI (acute myocardial infarction). Copeptin, derived from the C-terminal portion of the precursor to AVP (arginine vasopressin), is secreted stoichiometrically with vasopressin, hence it can be used as a surrogate marker of the AVP system. In the present study, 706 healthy volunteers were recruited from a local HF screening study. Participants with a history of cardiovascular disease and those with echocardiographic abnormalities were excluded from the study. Copeptin and NTproBNP levels were assayed using in-house immunoluminometric assays. Median copeptin levels were significantly higher in the male volunteers compared with the females [median (range): 4.3 (0.4\u201344.3) compared with 3.2 (1.0\u201314.8) pmol\/l; P&amp;lt;0.001]. In males, copeptin was correlated with eGFR (estimated glomerular filtration rate; rs=\u22120.186, P&amp;lt;0.001). In females, the correlation of copeptin with eGFR was weak (rs=\u22120.097, P=0.095). DT (deceleration time) and left atrial size correlated with higher copeptin levels (rs=0.085, P=0.029 and rs=0.206, P&amp;lt;0.001 respectively). Only gender (P&amp;lt;0.001), eGFR (P&amp;lt;0.001), left atrial size (P=0.04) and DT (P=0.02) remained independently predictive of plasma copeptin. The present study suggests that gender and renal function specific partition values should be used to interpret copeptin values in future studies of this biomarker in HF or ischaemic heart disease.<\/jats:p>","DOI":"10.1042\/cs20080140","type":"journal-article","created":{"date-parts":[[2008,7,23]],"date-time":"2008-07-23T09:51:54Z","timestamp":1216806714000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Gender and renal function influence plasma levels of copeptin in healthy individuals"],"prefix":"10.1042","volume":"116","author":[{"given":"Sanjay\u00a0S.","family":"Bhandari","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7LX, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Loke","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7LX, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan\u00a0E.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7LX, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian\u00a0B.","family":"Squire","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7LX, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[{"name":"B.R.A.H.M.S. Aktiengesellschaft, Hennigsdorf, 16761 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong\u00a0L.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7LX, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2009,1,8]]},"reference":[{"key":"2021113010114228000_B1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2021113010114228000_B2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/bmj.324.7352.1498","article-title":"Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations","volume":"324","author":"Hobbs","year":"2002","journal-title":"Br. Med. J."},{"key":"2021113010114228000_B3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.HYP.0000170140.36633.8f","article-title":"Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP","volume":"46","author":"Luchner","year":"2005","journal-title":"Hypertension"},{"key":"2021113010114228000_B4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2005.10.038","article-title":"Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure","volume":"47","author":"Tsutamoto","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010114228000_B5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(02)02059-4","article-title":"Plasma brain natriuretic peptide concentration: impact of age and gender","volume":"40","author":"Redfield","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010114228000_B6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.105.555573","article-title":"Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study","volume":"112","author":"Das","year":"2005","journal-title":"Circulation"},{"key":"2021113010114228000_B7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cardfail.2006.09.004","article-title":"Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure","volume":"13","author":"Gegenhuber","year":"2007","journal-title":"J. Card. Failure"},{"key":"2021113010114228000_B8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1161\/CIRCULATIONAHA.106.685503","article-title":"C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study","volume":"115","author":"Khan","year":"2007","journal-title":"Circulation"},{"key":"2021113010114228000_B9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin. Chem."},{"key":"2021113010114228000_B10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00003495-200363030-00001","article-title":"Management of vasodilatory shock: defining the role of arginine vasopressin","volume":"63","author":"Wenzel","year":"2003","journal-title":"Drugs"},{"key":"2021113010114228000_B11","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1172\/JCI107423","article-title":"Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma","volume":"52","author":"Robertson","year":"1973","journal-title":"J. Clin. Invest."},{"key":"2021113010114228000_B12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/01.HYP.5.2_Pt_2.I129","article-title":"Plasma and platelet vasopressin in essential hypertension and congestive heart failure","volume":"5","author":"Preibisz","year":"1983","journal-title":"Hypertension"},{"key":"2021113010114228000_B13","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1681\/ASN.2007020199","article-title":"Evaluation of the modification of diet in renal disease study equation in a large diverse population","volume":"18","author":"Stevens","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010114228000_B14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms","volume":"2","author":"Schiller","year":"1989","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"2021113010114228000_B15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurheartj\/14.suppl_D.8","article-title":"Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease","volume":"14","author":"Devereux","year":"1993","journal-title":"Eur. Heart J."},{"key":"2021113010114228000_B16","first-page":"151","article-title":"Guidelines for the management of hypertension","volume":"17","author":"Guidelines Subcommittee World Health Organization\/International Society of Hypertension (WHO\/ISH)","year":"1999","journal-title":"J. Hypertens."},{"key":"2021113010114228000_B17","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1161\/01.CIR.0000041661.63285.AE","article-title":"N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes","volume":"106","author":"Omland","year":"2002","journal-title":"Circulation"},{"key":"2021113010114228000_B18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1067\/mje.2000.106572","article-title":"Preload dependence of color M-mode Doppler flow propagation velocity in controls and in patients with left ventricular dysfunction","volume":"13","author":"M\u00f8ller","year":"2000","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"2021113010114228000_B19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2362.2006.01724.x","article-title":"Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure","volume":"36","author":"Stoiser","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"2021113010114228000_B20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2005.01.043","article-title":"Possible vascular role of increased plasma arginine vasopressin in congestive heart failure","volume":"106","author":"Nakamura","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"2021113010114228000_B21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2005.09.025","article-title":"Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction","volume":"47","author":"Costello-Boerrigter","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010114228000_B22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/heart.89.7.745","article-title":"The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population","volume":"89","author":"Raymond","year":"2003","journal-title":"Heart"},{"key":"2021113010114228000_B23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00019501-199910000-00016","article-title":"Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?","volume":"10","author":"Sayama","year":"1999","journal-title":"Coron. Artery Dis."},{"key":"2021113010114228000_B24","first-page":"61","article-title":"Plasma human brain natriuretic peptide in chronic renal failure","volume":"44","author":"Akiba","year":"1995","journal-title":"Clin. Nephrol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/116\/3\/257\/882578\/cs1160257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/116\/3\/257\/882578\/cs1160257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T10:19:57Z","timestamp":1638267597000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/116\/3\/257\/68662\/Gender-and-renal-function-influence-plasma-levels"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20080140","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,8]]}}}